Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 15, 2023

SELL
$16.75 - $48.98 $6,700 - $19,592
-400 Reduced 57.14%
300 $6.17 Million
Q1 2022

Apr 25, 2022

SELL
$30.71 - $45.71 $59,884 - $89,134
-1,950 Reduced 73.58%
700 $23,000
Q1 2021

Apr 14, 2021

SELL
$70.65 - $96.76 $5,298 - $7,257
-75 Reduced 2.75%
2,650 $198,000
Q4 2020

Jan 15, 2021

SELL
$58.41 - $89.06 $61,330 - $93,513
-1,050 Reduced 27.81%
2,725 $235,000
Q3 2020

Oct 14, 2020

SELL
$41.13 - $62.45 $20,565 - $31,225
-500 Reduced 11.7%
3,775 $230,000
Q2 2020

Jul 21, 2020

BUY
$25.95 - $43.15 $7,785 - $12,945
300 Added 7.55%
4,275 $177,000
Q1 2020

Apr 16, 2020

BUY
$26.15 - $77.24 $103,946 - $307,029
3,975 New
3,975 $114,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Westside Investment Management, Inc. Portfolio

Follow Westside Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Westside Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Westside Investment Management, Inc. with notifications on news.